TrialInvestigational new drugs2012

Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease.

Thomas Yau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.